Advances in prostate-specific membrane antigen PET of prostate cancer.

about

Development of a stress response therapy targeting aggressive prostate cancer.Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine

P2860

Q52714528-868ADF2D-0243-4F2D-A0FC-160F933BF650 Q57107703-53045DB9-9BE6-44F5-B75D-18092B0AB466

P2860

Advances in prostate-specific membrane antigen PET of prostate cancer.

Item

http://www.wikidata.org/entity/Q49713199

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Advances in prostate-specific membrane antigen PET of prostate cancer.

@en

Advances in prostate-specific membrane antigen PET of prostate cancer.

@nl

type

Item

label

Advances in prostate-specific membrane antigen PET of prostate cancer.

@en

Advances in prostate-specific membrane antigen PET of prostate cancer.

@nl

prefLabel

Advances in prostate-specific membrane antigen PET of prostate cancer.

@en

Advances in prostate-specific membrane antigen PET of prostate cancer.

@nl

P1476

Advances in prostate-specific membrane antigen PET of prostate cancer.

@en

P2093

Kirsten Bouchelouche

http://www.w3.org/2001/XMLSchema#string

Peter L Choyke

http://www.w3.org/2001/XMLSchema#string

P2860

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer

Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer

Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.

P31

scholarly article

P356

10.1097/CCO.0000000000000439

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29465429

http://www.w3.org/2001/XMLSchema#string

P932

6003670

http://www.w3.org/2001/XMLSchema#string

Advances in prostate-specific membrane antigen PET of prostate cancer.

about

P2860

P2860

Advances in prostate-specific membrane antigen PET of prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P932